Bluebird bio's first outcomes-based Medicaid agreement for sickle cell gene therapy, Lyfgenia, surges shares 9% in Michigan.

Bluebird bio shares surge 9% after announcing its first outcomes-based Medicaid agreement for sickle cell gene therapy, Lyfgenia, in Michigan. The company is in discussions with 15+ Medicaid agencies and has signed outcomes-based agreements with national commercial payers covering 200M people in the US. Lyfgenia, approved for sickle cell disease patients aged 12+, is in Phase 3 clinical studies.